2023 No. 6

2023 No.6

Theme Issue: Traditional Chinese Medicine and integrated traditional Chinese and Western Medicine therapy in integrated prevention and treatment of chronic hepatitis B:A review and prospect from the “11th Five - Year Plan”to the “13th Five - Year Plan”

Executive Chief Editor: YE Yongan

Liver Diseases Academy of Traditional Chinese Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

An integrated traditional Chinese and Western Medicine study on the comprehensive prevention and treatment of chronic hepatitis B and its related diseases

Yongan YE

2023, 39(6): 1257-1266. DOI: 10.3969/j.issn.1001-5256.2023.06.001

Abstract(744)

HTML (190)

PDF (2108KB)(129)

Abstract:
Chronic hepatitis B and its related diseases remain important public health problems and tough medical issues in China and even around the world, and now there is still a lack of effective radical treatment methods. This article reviews the traditional Chinese Medicine treatment regimens, the integr...

Discussions by Experts

Research advances in kidney-tonifying therapy for patients with HBeAg-positive chronic HBV infection

Yufeng XING, Zhiyi HAN, Daqiao ZHOU, Guangdong TONG

2023, 39(6): 1267-1273. DOI: 10.3969/j.issn.1001-5256.2023.06.002

Abstract(485)

HTML (137)

PDF (1760KB)(62)

Abstract:

Chronic HBV infection is an important phase in the natural history of HBV, but there are still controversies over the treatment of this stage. Traditional Chinese medicine has had unique advantages in the prevention and treatment of viral hepatitis since ancient times and plays an important role in ...

Clinical efficacy and mechanism of action of kidney-tonifying, spleen-strengthening, and diuresis-promoting therapy in treatment of chronic hepatitis B

Xiaojun ZHU, Jinghao ZHANG, Xuehua SUN, Xin ZHANG, Yueqiu GAO

2023, 39(6): 1274-1279. DOI: 10.3969/j.issn.1001-5256.2023.06.003

Abstract(485)

HTML (88)

PDF (1745KB)(54)

Abstract:
Chronic hepatitis B is a public health issue worldwide. Nucleotide analogues and interferon therapy can effectively inhibit HBV replication, but they still have the shortcomings such as inability to achieve the clearance of HBV cccDNA and low HBsAg clearance rate. The academic viewpoint of "kidney-t...

Role of traditional Chinese Medicine in prevention and treatment of chronic hepatitis B liver fibrosis: Current status, challenges, and thoughts

Meijie SHI, Huanming XIAO, Yubao XIE, Sheng LI, Folai ZENG, Xiaoling CHI

2023, 39(6): 1280-1286. DOI: 10.3969/j.issn.1001-5256.2023.06.004

Abstract(779)

HTML (106)

PDF (1918KB)(114)

Abstract:
In recent years, significant breakthroughs have been made in the research on the role of traditional Chinese medicine (TCM) in the prevention and treatment of chronic hepatitis B liver fibrosis. In terms of clinical research, several multicenter randomized double-blind controlled studies have been c...

Guideline

Chinese expert consensus on management of thrombocytopenia in cancer patients with liver injury (2022 edition)

Committee of Neoplastic Supportive-care (CONS), China Anti-Cancer Association

2023, 39(6): 1287-1294. DOI: 10.3969/j.issn.1001-5256.2023.06.005

Abstract(869)

HTML (212)

PDF (2739KB)(212)

Abstract:
Thrombocytopenia and liver injury are common and serious clinical problems in cancer patients. The etiology of thrombocytopenia in cancer patients with liver injury (TCLI) is complicated, which is common in liver injury and tumor treatment. The management of cancer therapy-induced thrombocytopenia h...

Guideline Interpretation

Debates on the natural history of chronic hepatitis B virus infection during the update of Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version)

Hui ZHUANG

2023, 39(6): 1295-1298. DOI: 10.3969/j.issn.1001-5256.2023.06.006

Abstract(982)

HTML (146)

PDF (1724KB)(270)

Abstract:
This article introduces the debates on the natural history of chronic hepatitis B virus (HBV) infection during the update of Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version), including nomenclature and definition, HBV infection, HBV DNA threshold for patients in the ...

Evolution in the indications for anti-viral therapy in chronic hepatitis B

Jinjin LIU, Mengyang ZHANG, Yameng SUN, Hong YOU

2023, 39(6): 1299-1303. DOI: 10.3969/j.issn.1001-5256.2023.06.007

Abstract(752)

HTML (132)

PDF (1730KB)(220)

Abstract:
In order to reduce the disease burden of chronic hepatitis B (CHB) and improve the treatment rate of CHB, the indications for anti-viral therapy have been gradually expanded and simplified in guidelines for the prevention and treatment of CHB released by Chinese Medical Association from 2005 to 2022...

Original Article_Viral Hepatitis

Liver inflammation and fibrosis in HBV-infected patients with a low viral load

Manlei JIANG, Fei XU, Lunli ZHANG

2023, 39(6): 1304-1307. DOI: 10.3969/j.issn.1001-5256.2023.06.008

Abstract(586)

HTML (57)

PDF (1724KB)(80)

Abstract:
Objective To investigate liver inflammation and fibrosis in patients with chronic HBV infection with a low viral load. Methods Among the HBsAg-positive patients who attended Ganzhou Fifth People's Hospital from April 2019 to June 2022, 41 patients with 20 IU/mL < HBV DNA < 2 000 IU/mL were sel...

Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure

Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG

2023, 39(6): 1308-1312. DOI: 10.3969/j.issn.1001-5256.2023.06.009

Abstract(388)

HTML (79)

PDF (1996KB)(47)

Abstract:
Objective To investigate the association between platelet count (PLT) and the prognosis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), to establish a new PLT-related scoring model, and to assess its value in predicting the short-term prognosis of HBV-ACLF. Methods A retrospe...

Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B

Yuanmei CHE, Ai LI, Liang WANG, Lunli ZHANG, Xiaopeng LI

2023, 39(6): 1313-1317. DOI: 10.3969/j.issn.1001-5256.2023.06.010

Abstract(823)

HTML (82)

PDF (1738KB)(92)

Abstract:
Objective To investigate the possible influence of long-term antiviral therapy with entecavir on renal function in patients with chronic hepatitis B (CHB) and the sensitive indicators for early identification of renal injury. Methods A cross-sectional real-world study was conducted for the clinical ...

Original Article_Fatty Liver Disease

Value of Helicobacter pylori infection combined with traditional risk factors in predicting the risk of metabolic associated fatty liver disease

Sarula BAO, Xiaoxu DU, Hongyan GE

2023, 39(6): 1318-1324. DOI: 10.3969/j.issn.1001-5256.2023.06.011

Abstract(423)

HTML (131)

PDF (1769KB)(66)

Abstract:
Objective To investigate the association between Helicobacter pylori (HP) infection and newly named "metabolic associated fatty liver disease (MAFLD)" and the value of HP infection combined with traditional risk factors in predicting MAFLD. Methods A retrospective analysis was performed for the clin...

Value of atherogenic index of plasma in predicting metabolic associated fatty liver disease in patients with type 2 diabetes mellitus

Mengya GAO, Qian QIN, Shoujun WANG

2023, 39(6): 1325-1331. DOI: 10.3969/j.issn.1001-5256.2023.06.012

Abstract(423)

HTML (399)

PDF (2586KB)(46)

Abstract:
Objective To investigate the association between atherogenic index of plasma (AIP) and metabolic associated fatty liver (MAFLD) in type 2 diabetes mellitus (T2DM). Methods A total of 375 patients with T2DM who were hospitalized and treated in Department of Endocrinology, The First Affiliated Hospita...

Clinical features of hypopituitarism with nonalcoholic fatty liver disease after sellar tumor surgery in children

Tingting DU, Hui YAO, Xiaohong CHEN, Jie LUO, Luhong YANG, Lifang FENG, Xiaoqian CHEN, Man HU, Juan LUO

2023, 39(6): 1332-1339. DOI: 10.3969/j.issn.1001-5256.2023.06.013

Abstract(450)

HTML (101)

PDF (1762KB)(37)

Abstract:
Objective To investigate the clinical features of hypopituitarism with nonalcoholic fatty liver disease (NAFLD) in children after sellar tumor surgery and the association between hypopitarism and NAFLD in children. Methods A retrospective analysis was performed for the clinical data of children with...

Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet

Yijing XIN, Yiyun CHEN, Hailin YANG, Yunhui ZHUO, Dingqi ZHANG, Fengfeng ZHOU

2023, 39(6): 1340-1350. DOI: 10.3969/j.issn.1001-5256.2023.06.014

Abstract(615)

HTML (259)

PDF (4624KB)(45)

Abstract:
Objective To investigate the intervention effect of Xuanfuhua decoction on mice with nonalcoholic steatohepatitis (NASH) induced by high-fat, high-fructose, and high-cholesterol diet. Methods A total of 32 male C57/BL6J mice were randomly divided into normal group, model group, Xuanfuhua decoction g...

Original Article_Liver Fibrosis and Liver Cirrhosis

Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells

Yuxin YAN, Xiaoyang GAO, Chunyan ZHANG, Rong JIN, Hongwei YUAN, Yuehong MA

2023, 39(6): 1351-1357. DOI: 10.3969/j.issn.1001-5256.2023.06.015

Abstract(486)

HTML (87)

PDF (2342KB)(31)

Abstract:
Objective To investigate the role and mechanism of action of Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells using cell experiment. Methods A total of 20 Wistar rats were randomly divided into control group and administration group, with 10 rats in each group. The rats i...

Original Article_Other Liver Disease

Clinical features of patients with drug-induced liver injury in Shaanxi Province from 2009 to 2019

Qian WANG, Mimi LIU, Kaini HE, Xiaoyan GUO

2023, 39(6): 1358-1365. DOI: 10.3969/j.issn.1001-5256.2023.06.016

Abstract(1096)

HTML (313)

PDF (2639KB)(134)

Abstract:
Objective To investigate the clinical features of patients with drug-induced liver injury (DILI). Methods A retrospective analysis was performed for the clinical data of 1 376 patients with DILI who were admitted to 20 hospitals in Shaanxi Province, China, from 2009 to 2019 and were diagnosed with R...

Distribution and drug resistance of pathogenic bacteria for infection after liver transplantation

Duo HAN, Hong HE, Hongwei WANG, Tingting TIAN, Jing LI

2023, 39(6): 1366-1373. DOI: 10.3969/j.issn.1001-5256.2023.06.017

Abstract(557)

HTML (143)

PDF (3720KB)(58)

Abstract:
Objective To investigate the distribution and drug resistance of pathogenic bacteria for infection after liver transplantation, and to provide a scientific basis for the rational clinical application of antibiotics. Methods The pathogenic bacteria isolated from the specimens of 904 patients with inf...

Original Article_Pancreatic Disease

Influencing factors for dynamic changes in the severity of fatty liver in patients with acute pancreatitis and fatty liver

Qiang CHEN, Mingkuan JIANG, Miao ZHANG, Lin LUO, Lirong ZHANG

2023, 39(6): 1374-1381. DOI: 10.3969/j.issn.1001-5256.2023.06.018

Abstract(378)

HTML (80)

PDF (1811KB)(26)

Abstract:
Objective To investigate the dynamic change of fatty liver (FL) in patients with fatty liver-related acute pancreatitis (FLAP) and related influencing factors. Methods A total of 136 FLAP patients who were admitted to The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University...

Influencing factors for persistent inflammation, immunosuppression, and catabolism syndrome in patients with severe acute pancreatitis and establishment of a predictive model

Chan LI, Zhihai LIANG, Guodu TANG

2023, 39(6): 1382-1390. DOI: 10.3969/j.issn.1001-5256.2023.06.019

Abstract(476)

HTML (138)

PDF (3410KB)(37)

Abstract:
Objective To investigate the influencing factors for persistent inflammation, immunosuppression, and catabolism syndrome (PICS) in patients with severe acute pancreatitis(SAP), and to establish a predictive model. Methods A retrospective analysis was performed for the clinical data of 163 patients w...

Value of five scoring systems in predicting the severity of hyperlipidemic acute pancreatitis: A comparative analysis

Yuanzhen WANG, Yaling YUN, Juan XIE, Liya HUANG

2023, 39(6): 1391-1397. DOI: 10.3969/j.issn.1001-5256.2023.06.020

Abstract(474)

HTML (87)

PDF (2228KB)(42)

Abstract:
Objective To investigate the value of pancreatitis activity scoring system (PASS) score, Bedside Index for Severity in Acute Pancreatitis (BISAP) score, Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE-Ⅱ) score, harmless acute pancreatitis score (HAPS), and Ranson score in evaluating the sev...

Value of atherogenic index of plasma combined with Bedside Index for Severity in Acute Pancreatitis in the early prediction of severe hypertriglyceridemic acute pancreatitis

Qi JI, Xi HUANG, Chenyi SHE, Song ZHANG, Weitian XU, Qingming WU

2023, 39(6): 1398-1403. DOI: 10.3969/j.issn.1001-5256.2023.06.021

Abstract(471)

HTML (73)

PDF (2004KB)(39)

Abstract:
Objective To investigate the correlation between atherogenic index of plasma (AIP) and the severity of hypertriglyceridemic acute pancreatitis (HTG-AP) and the value of AIP combined with Bedside Index for Severity in Acute Pancreatitis (BISAP) score in the early prediction of severe HTG-AP (sHTG-AP)...

Case Report

A case of primary biliary cholangitis with connective tissue disease and immune thrombocytopenia

Qingxia LIU, Chenggang ZHANG, Haolin TANG, Wenjing QU, Huifan JI, Xiaolin GUO

2023, 39(6): 1404-1407. DOI: 10.3969/j.issn.1001-5256.2023.06.022

Abstract(485)

HTML (107)

PDF (1904KB)(59)

Abstract:

Congenital left hepatic deficiency with hepatocellular carcinoma: A case report

Hailin WANG, Jingdong LI, Guo WU

2023, 39(6): 1408-1410. DOI: 10.3969/j.issn.1001-5256.2023.06.023

Abstract(453)

HTML (92)

PDF (2003KB)(35)

Abstract:

Multidisciplinary diagnosis and treatment of primary hepatic neuroendocrine tumor

Kaiyue ZHAO, Zhe YAN, Yuan HUANG

2023, 39(6): 1411-1413. DOI: 10.3969/j.issn.1001-5256.2023.06.024

Abstract(405)

HTML (74)

PDF (2153KB)(37)

Abstract:

Cavernous transformation of the portal vein caused by myeloproliferative disease: A case report

Bing HAN, Chuantao TU

2023, 39(6): 1414-1417. DOI: 10.3969/j.issn.1001-5256.2023.06.025

Abstract(402)

HTML (121)

PDF (2374KB)(29)

Abstract:

Review

Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection

Yuxia ZHOU, Caihong WANG, Xiaowen YAO, Rong WANG, Xiaofeng ZHENG, Xiaohui YU, Jiucong ZHANG

2023, 39(6): 1418-1423. DOI: 10.3969/j.issn.1001-5256.2023.06.026

Abstract(421)

HTML (214)

PDF (2165KB)(26)

Abstract:
Persistent HBV infection alters the expression of receptors on the surface of innate and acquired immune cells, which may cause a variety of immune disorders and finally lead to immune escape and disease chronicity. Studies have shown that the upregulation of inhibitory receptors is the main cause o...

Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation

Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU

2023, 39(6): 1424-1430. DOI: 10.3969/j.issn.1001-5256.2023.06.027

Abstract(513)

HTML (152)

PDF (2118KB)(53)

Abstract:
In recent years, monotherapy and combination therapy with immune checkpoint inhibitors (ICIs) have achieved good efficacy in a variety of malignancies from solid tumors to lymphomas and have become a standardized and systematic treatment modality for many cancers. However, there is still a lack of s...

Research advances in cytomegalovirus hepatitis

Qinghe ZENG, Yan MENG, Yuxiang LI

2023, 39(6): 1431-1439. DOI: 10.3969/j.issn.1001-5256.2023.06.028

Abstract(971)

HTML (105)

PDF (2175KB)(127)

Abstract:
Cytomegalovirus hepatitis is a liver disease caused by human cytomegalovirus infection and is one of the most common liver diseases in children and immunocompromised individuals. This disease has no specific clinical manifestations and is easily confused with other types of viral hepatitis, which ma...

Role of intrahepatic microenvironment induced-autophagy in nonalcoholic fatty liver disease

Xuanxuan KOU, Hua ZHANG, Jingxin DENG, Jiangang ZHANG

2023, 39(6): 1440-1445. DOI: 10.3969/j.issn.1001-5256.2023.06.029

Abstract(571)

HTML (192)

PDF (1858KB)(36)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a series of abnormal liver lesions mainly characterized by excessive lipid deposition in hepatocytes, and it is also the most common chronic liver disease worldwide. Autophagy is a basic cellular process in which cells degrade their own components and part...

Research advances in nonalcoholic fatty liver disease in individuals with HIV infection

Jiajun LU, Fazhu FEI, Bin REN

2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030

Abstract(492)

HTML (115)

PDF (1816KB)(77)

Abstract:

The prevalence rate of nonalcoholic fatty liver disease (NAFLD) tends to increase in the general population around the world, and the incidence rate of liver malignancies caused by NAFLD is also increasing continuously. Obesity is an independent risk factor for NAFLD. Among the individuals with HIV ...

Research advances in the cascade interaction between reactive oxygen species/reactive nitrogen species and the NF-κB signaling pathway in liver fibrosis

Yuanqian MIN, Shan LI, Xianghua LIU, Yi YANG, Ningning LI, Baoping LU

2023, 39(6): 1454-1460. DOI: 10.3969/j.issn.1001-5256.2023.06.031

Abstract(924)

HTML (313)

PDF (2107KB)(51)

Abstract:
Liver fibrosis is a compensatory response in the process of tissue repair after chronic liver injury, and it is also a necessary pathological process in the progression of a variety of chronic liver diseases. In the pathological state, the imbalance between hepatic oxidative system and antioxidant s...

Advances in the pathogenesis, diagnosis, and treatment of renal injury in liver cirrhosis

Qingqing LIU, Jing YANG, Shaoshan HU, Pingju LI, Qiu JIN, Honglin MA

2023, 39(6): 1461-1467. DOI: 10.3969/j.issn.1001-5256.2023.06.032

Abstract(576)

HTML (144)

PDF (1755KB)(59)

Abstract:
Patients with decompensated cirrhosis often have a reduction in renal function due to severe hepatic insufficiency which results in reduced inactivation of vasodilators, hemodynamic disorders, immune disorders, and infections, and without timely intervention, patients may gradually develop from earl...

Research advances in early screening and diagnosis of hepatocellular carcinoma

Jiaxin HAN, Yuqiang MI, Liang XU

2023, 39(6): 1468-1475. DOI: 10.3969/j.issn.1001-5256.2023.06.033

Abstract(902)

HTML (185)

PDF (1928KB)(157)

Abstract:
For the high-risk population, early screening and diagnosis are important measures to achieve good control of liver cancer and reduce the burden of liver cancer, and determining the high-risk population of liver cancer and formulating appropriate liver cancer screening strategies are the key to real...

Research advances in natural killer cell-based immunotherapy in liver cancer

Shiji CHENG, Tianrui KUANG, Keshuai DONG, Jia YU

2023, 39(6): 1476-1481. DOI: 10.3969/j.issn.1001-5256.2023.06.034

Abstract(841)

HTML (193)

PDF (1747KB)(83)

Abstract:
Natural killer (NK) cells are important immune cells in the human body and are also the main lymphocytes in the liver. They are considered the first defense mechanism against tumor and have a significant impact on the development and progression of liver cancer. The characteristics of NK cells help ...

Current research status of left-sided portal hypertension after superior mesenteric-portal vein confluence pancreaticoduodenectomy

Hong ZOU, Qiao ZHU, Yi WEN, Hongyin LIANG, Mingmei ZHOU, Kehui SHI, Jun WU, Lijun TANG

2023, 39(6): 1482-1487. DOI: 10.3969/j.issn.1001-5256.2023.06.035

Abstract(563)

HTML (112)

PDF (2120KB)(31)

Abstract:
Surgical operation is the main treatment method for pancreatic cancer, and in clinical practice, radical surgery for pancreatic cancer is often combined with superior mesenteric-portal vein confluence pancreaticoduodenectomy to achieve R0 resection. However, severe left-sided portal hypertension (LS...

Role of purine signaling in liver immune regulation

Faxiang MA, Zhengkun TU

2023, 39(6): 1488-1496. DOI: 10.3969/j.issn.1001-5256.2023.06.036

Abstract(571)

HTML (448)

PDF (2540KB)(45)

Abstract:
Purines are mainly composed of ATP, NAD⁺, and nucleic acid. In addition to their key intracellular functions, NAD⁺, ATP, and their hydrolyzed products (including ADP, AMP, and adenosine) are important extracellular signals involved in physiological processes and pathological conditions. Purine signa...

Research advances in the pathogenesis, phenotype-genotype relationship, and pharmacotherapy of hepatolenticular degeneration

Aierkenjiang MALIPATI, Kuerban KAIDIRIYA, Ling XU, Xiaofeng SUN

2023, 39(6): 1497-1504. DOI: 10.3969/j.issn.1001-5256.2023.06.037

Abstract(874)

HTML (474)

PDF (2259KB)(89)

Abstract:
In hepatolenticular degeneration, also known as Wilson's disease (WD), the binding of copper to ceruloplasmin is impaired, resulting in the deposition of free copper mainly in the liver, brain, and other organs. The prevalence rate of WD was 1/30 000. In clinical practice, most WD patients are young...

Thanks

Current reviewers

2023, 39(6): 1357-1357. DOI: 10.3969/j.issn.1001-5256.2023.6.zhixie1

Abstract(191)

HTML (78)

PDF (767KB)(19)

Abstract: